Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press68810.17650/1726-9776-2017-13-2-56-62DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиTargeted therapy of advanced renal cell carcinomaТаргетная терапия распространенного почечно-клеточного ракаPopovA. M.ПоповА. М.
Russian Federation

15 Marshala Timoshenko St., Moscow 121359

Александр Михайлович Попов 

121359 Москва, ул. Маршала Тимошенко, 15 

palexdoc@yandex.ruCentral Clinical Hospital, Administration of the President of the RussiaФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской Федерации3006201713256621906201719062017https://oncourology.abvpress.ru/oncur/article/view/688

The standard method of treatment of patients with metastatic renal cell carcinoma is targeted therapy. Selection of drugs for these patients has remained a complex task. In the absence of predictors of effectiveness, clinical trials should serve as a reference point. 

Стандартным методом лечения пациентов, страдающих метастатическим почечно-клеточным раком, является таргетная терапия. Выбор препаратов для таких больных остается сложной задачей. В отсутствие предикторов эффективности следует ориентироваться на результаты клинических исследований. 

kidney cancertargeted therapylenvatinibnivolumabрак почкитаргетная терапияленватинибниволумаб1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Malignant tumors in Russia in 2015 (morbidity and fatality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Malignant tumors in Russia in 2015 (morbidity and fatality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].2. Михайленко Д.С., Алексеев Б.Я., Ефремов Г.Д., Каприн А.Д. Генетические особенности несветлоклеточного рака почки. Онкоурология 2016;12(3): 14–21. [Mikhaylenko D.S., Alekseev B.Ya., Efremov G.D., Kaprin A.D. Genetic characteristics of the non-clear cell renal cancer. Onkourologiya = Cancer Urology 2016;12(3):14–21. (In Russ.)]. DOI: 10.17650/1726-9776-2016-12-3-14-21.Михайленко Д.С., Алексеев Б.Я., Ефремов Г.Д., Каприн А.Д. Генетические особенности несветлоклеточного рака почки. Онкоурология 2016;12(3): 14–21. [Mikhaylenko D.S., Alekseev B.Ya., Efremov G.D., Kaprin A.D. Genetic characteristics of the non-clear cell renal cancer. Onkourologiya = Cancer Urology 2016;12(3):14–21. (In Russ.)]. DOI: 10.17650/1726-9776-2016-12-3-14-21.3. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; (Suppl 5):58–68. DOI: 10.1093/annonc/mdw328. PMID: 27664262.Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; (Suppl 5):58–68. DOI: 10.1093/annonc/mdw328. PMID: 27664262.4. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356(2):115–24. DOI: 10.1056/NEJMoa065044. PMID: 17215529.Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356(2):115–24. DOI: 10.1056/NEJMoa065044. PMID: 17215529.5. Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8. DOI: 10.1200/JCO.2009.23.9764. PMID: 20100962.Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8. DOI: 10.1200/JCO.2009.23.9764. PMID: 20100962.6. Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103–11. DOI: 10.1016/S0140-6736(07)61904-7. PMID: 18156031.Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103–11. DOI: 10.1016/S0140-6736(07)61904-7. PMID: 18156031.7. Rini B.I., Halabi S., Rosenberg J.E. at al. Phase III trial bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. DOI: 10.1200/JCO.2009.26.5561. PMID: 20368558.Rini B.I., Halabi S., Rosenberg J.E. at al. Phase III trial bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. DOI: 10.1200/JCO.2009.26.5561. PMID: 20368558.8. Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon-alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90. DOI: 10.1200/JCO.2008.20.1293. PMID: 19487381.Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon-alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90. DOI: 10.1200/JCO.2008.20.1293. PMID: 19487381.9. Escudier B., Bellmunt J., Negrier S. et al. Phase III trial bevacizumab plus interferon alfa in patients with metastatic renal cell carcinoma (AVOREN): final results of overall survival. J Clin Oncol 2010;28(13):2144–50. DOI: 10.1200/JCO.2009.26.7849. PMID: 20368553.Escudier B., Bellmunt J., Negrier S. et al. Phase III trial bevacizumab plus interferon alfa in patients with metastatic renal cell carcinoma (AVOREN): final results of overall survival. J Clin Oncol 2010;28(13):2144–50. DOI: 10.1200/JCO.2009.26.7849. PMID: 20368553.10. Sternberg C.N., Hawkins R.E., Wagstaff J. et al. A randomized, double-blind, phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287–96. DOI: 10.1016/j.ejca.2012.12.010. PMID: 23321547.Sternberg C.N., Hawkins R.E., Wagstaff J. et al. A randomized, double-blind, phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287–96. DOI: 10.1016/j.ejca.2012.12.010. PMID: 23321547.11. Motzer R.J., Hutson T.E., McCann L. et al. Overall survival in renal cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;370(18):1769–70. DOI: 10.1056/NEJMc1400731. PMID: 24785224.Motzer R.J., Hutson T.E., McCann L. et al. Overall survival in renal cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;370(18):1769–70. DOI: 10.1056/NEJMc1400731. PMID: 24785224.12. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81. DOI: 10.1056/NEJMoa066838. PMID: 17538086.Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81. DOI: 10.1056/NEJMoa066838. PMID: 17538086.13. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer. Version 2.2017, 2016. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer. Version 2.2017, 2016. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.14. Rini B.I., Escuder B., Тomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931–9. DOI: 10.1016/S0140-6736(11)61613-9. PMID: 22056247.Rini B.I., Escuder B., Тomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931–9. DOI: 10.1016/S0140-6736(11)61613-9. PMID: 22056247.15. Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI: 10.1056/NEJMoa1510665. PMID: 26406148.Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI: 10.1056/NEJMoa1510665. PMID: 26406148.16. Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal-cell carcinoma: a randomized, phase II, open-label, multicenter trial. Lancet Oncol 2015;16(15):1473–82. DOI: 10.1016/S1470-2045(15)00290-9. PMID: 26482279.Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal-cell carcinoma: a randomized, phase II, open-label, multicenter trial. Lancet Oncol 2015;16(15):1473–82. DOI: 10.1016/S1470-2045(15)00290-9. PMID: 26482279.17. Hutson T.E., Bellmunt J., Porta C. et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010;46(13):2432–40. DOI: 10.1016/j.ejca.2010.06.121. PMID: 20656473.Hutson T.E., Bellmunt J., Porta C. et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010;46(13):2432–40. DOI: 10.1016/j.ejca.2010.06.121. PMID: 20656473.18. Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256–65. DOI: 10.1002/cncr.25219. PMID: 20549832.Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256–65. DOI: 10.1002/cncr.25219. PMID: 20549832.19. Sherman S., Amzal B., Calvo E. et al. An undirect comparison of everolimus versus axitinib in US patients with advanced renal cell carcinoma in whom prior sunitinib therapy failed. Clin Ther 2015;37(11):2552–9. DOI: 10.1016/j.clinthera.2015.09.013. PMID: 26602976.Sherman S., Amzal B., Calvo E. et al. An undirect comparison of everolimus versus axitinib in US patients with advanced renal cell carcinoma in whom prior sunitinib therapy failed. Clin Ther 2015;37(11):2552–9. DOI: 10.1016/j.clinthera.2015.09.013. PMID: 26602976.20. Инструкция по медицинскому применению препарата Ленвима. Регистрационный номер ЛП-003398 от 29.12.2015 (с изменениями от 06.12.2016). [Full prescribing information for Lenvima. Registration number: LP-003398 (with amendments from 06.12.2016). (In Russ.)].Инструкция по медицинскому применению препарата Ленвима. Регистрационный номер ЛП-003398 от 29.12.2015 (с изменениями от 06.12.2016). [Full prescribing information for Lenvima. Registration number: LP-003398 (with amendments from 06.12.2016). (In Russ.)].21. Инструкция по медицинскому применению препарата Ниволумаб. Регистрационный номер ЛП-004026-221216. [Full prescribing information for Nivolumab. Registration number: LP-004026-221216. (In Russ.)].Инструкция по медицинскому применению препарата Ниволумаб. Регистрационный номер ЛП-004026-221216. [Full prescribing information for Nivolumab. Registration number: LP-004026-221216. (In Russ.)].